Taken with the previous mouse FXS model study showing specific upregulation of secreted MMP-9, reduced upon minocycline treatment, the combined data set strongly suggests that minocycline is inhibiting MMPs to exert its alleviatory actions on FXS phenotypes [51, 53]. The gene discussed is MMP9; the disease is fragile X syndrome.